# AnaBios Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anabios-corporation

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.anabios.com
- Total disclosed funding: $12M
- Latest round: Series C (May 25, 2022)
- Investors on record: 2

## About

AnaBios Corporation, Inc. is a biotechnology company focused on providing high-quality human tissues and cells for scientific research and drug discovery, enhancing the development of safer pharmaceuticals.Founded in 2009 and headquartered in San Diego, US, AnaBios Corporation specializes in the provision of human tissues for research purposes. The company has executed a total of 5 deals since its inception, with the most recent transaction occurring on May 25, 2022. This involved a Series C funding round of USD 6.50 mn led by Ampersand Capital Partners, bringing the total amount raised to USD 6.50 mn and valuing the company at USD 36.261 mn. The company's founder is Jack Reynolds, and the current CEO is Andre Ghetti.AnaBios specializes in providing high-quality human tissues and cells, primarily for scientific research and drug discovery. Their core offerings include various types of human tissues such as hepatocytes, precision-cut lung slices, and spinal cord tissue, recovered through a vast network of hospitals and organ procurement organizations. The company employs proprietary methods to preserve the physiological function of these tissues, enabling researchers to conduct studies that closely resemble human biology. These products support advancements in drug development, allowing researchers to create safer and more effective pharmaceuticals while minimizing time-to-market and development costs. AnaBios serves a global client base, focusing on pharmaceutical and biotechnology companies involved in research and drug discovery, with a significant presence in North America, Europe, and Asia.AnaBios generates revenue through direct transactions with a client base that includes pharmaceutical and biotechnology companies utilizing their human tissues and cells for research purposes. The transaction structure typically involves B2B agreements, where clients procure specific tissue types or services on a contractual basis. Revenue comes from the sale of individual products or ongoing research collaborations, with established pricing plans for flagship products such as CardioPRIME heart tissue assays and neurotoxicity functional assays.In May 2022, AnaBios Corporation, Inc. raised USD 6.50 mn in Series C funding from Ampersand Capital Partners. The company plans to use this funding to expand its operations and possibly introduce new products, although specific launch dates are not mentioned. Expansion targets include new markets in North America, Europe, and Asia, in line with their current client base and strategic objectives.

## Funding rounds

- Series C, May 25, 2022, $6.5M — Ampersand
- Series B, May 18, 2016, $5.1M — Xyence Capital

## Investors

- Xyence Capital (https://capitalatlas.ai/funds/xyence-capital) — Series B
- Ampersand (https://capitalatlas.ai/funds/ampersand) — Series C